BL-M24D1 for advanced head and neck and other solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label, multicenter, non-randomized Phase I trial uses dose escalation (Phase Ia) followed by dose-expansion cohorts (Phase Ib) to characterize safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of BL-M24D1. Phase Ia escalates doses to identify a recommended dose for Phase Ib, which enrolls expansion cohorts at selected doses. Eligible adults must have measurable locally advanced or metastatic head and neck squamous cell carcinoma or other solid tumors, ECOG 0–1, adequate organ function, and provide recent tumor tissue for biomarker work. The investigational agent is given as monotherapy with regular safety monitoring, imaging per RECIST v1.1, and pharmacokinetic assessments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntarily sign the informed consent form and comply with the protocol requirements;
2. Gender unrestricted;
3. Age: ≥18 years and ≤75 years (Phase Ia); ≥18 years (Phase Ib);
4. Expected survival time ≥3 months;
5. Patients with locally advanced or metastatic head and neck squamous cell carcinoma and other solid tumors;
6. Agree to provide archived tumor tissue specimens or fresh tissue samples from the primary or metastatic foci within the past 3 years;
7. Must have at least one measurable lesion meeting the RECIST v1.1 criteria;
8. ECOG performance status score of 0 or 1;
9. Toxicities from prior antitumor therapy have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
10. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
11. Organ function levels must meet the requirements;
12. Coagulation function: International Normalized Ratio ≤1.5, and activated partial thromboplastin time ≤1.5 × ULN;
13. Urine protein ≤2+ or ≤1000mg/24h;
14. For premenopausal women with childbearing potential, a serum pregnancy test must be performed within 7 days before starting treatment, and the result must be negative. Patients must not be lactating. All enrolled patients (regardless of gender) should adopt adequate barrier contraception throughout the treatment cycle and for 6 months after treatment ends.

Exclusion Criteria:

1. Use of chemotherapy, biotherapy, or immunotherapy within 4 weeks or 5 half-lives prior to the first dose;
2. History of severe heart disease;
3. QT interval prolongation, complete left bundle branch block, or third-degree atrioventricular block;
4. Active autoimmune or inflammatory diseases;
5. Diagnosis of other malignancies within 5 years prior to the first dose;
6. Hypertension poorly controlled by two antihypertensive medications;
7. Poorly controlled blood glucose levels;
8. Unstable thrombotic events requiring therapeutic intervention within 6 months prior to the first dose;
9. Lung diseases graded ≥3 according to CTCAE v5.0;
10. Symptoms of active central nervous system metastasis;
11. History of allergy to recombinant humanized antibodies or human-mouse chimeric antibodies, or allergy to any excipient component of BL-M24D1;
12. Previous organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT);
13. Cumulative anthracycline dose \>360 mg/m² during prior (neo)adjuvant anthracycline therapy;
14. Positive human immunodeficiency virus antibody, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
15. History of interstitial lung disease (ILD) requiring steroid treatment, or current ILD;
16. Active infection requiring systemic treatment within 4 weeks prior to the first dose; lung infection within 2 weeks prior to the first dose;
17. Pleural, abdominal, pelvic, or pericardial effusion requiring drainage and/or accompanied by symptoms within 4 weeks prior to the first dose;
18. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to the first dose;
19. Participation in another clinical trial within 4 weeks prior to the first dose;
20. Pregnant or lactating women;
21. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.

Where it's running

• West China Hospital of Sichuan University
  Chengdu, Sichuan, China Recruiting

Study contacts

• Study coordinator: Sa Xiao, PHD
• Email: xiaosa@baili-pharm.com
• Phone: 15013238943

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

• IBI3028 in advanced solid tumors

  This phase 1 study tests IBI3028 in adults with unresectable or metastatic solid tumors to see if it is safe and how patients tolerate it.

  Recruiting Phase 1 Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Tianjin, Tianjin Municipality · NCT07589205

• TER-2013 for advanced solid tumors with AKT/PI3K/PTEN pathway changes

  This trial tests whether TER-2013, alone or with fulvestrant, is safe and can help people with advanced breast, ovarian, endometrial, lung, or head-and-neck cancers that have AKT/PI3K/PTEN pathway alterations.

  Recruiting at 20 sites Phase 1/2 Terremoto Biosciences Inc. · Duarte, California and 24 other locations · NCT07109726

• Imaging study using two antibody fragments in patients with solid tumors

  This study is testing two special antibody fragments in people with solid tumors to see how well they target cancer cells and how they move through the body.

  Recruiting Early Phase 1 Var2 Pharmaceuticals · Groningen, Provincie Groningen · NCT06645808

• MQ710 with or without pembrolizumab for advanced skin and other solid tumors

  This will test different doses of MQ710, alone or together with pembrolizumab, in adults with advanced or recurrent solid tumors (including skin cancers) to find a safe dose with mild side effects.

  Recruiting at 5 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05859074

• Combining TU2218 with KEYTRUDA for advanced solid tumors

  This study is testing a new treatment combining TU2218 and KEYTRUDA to see if it can help people with advanced solid tumors who haven't responded to other therapies.

  Recruiting at 8 sites Phase 1/2 TiumBio Co., Ltd. · San Antonio, Texas and 10 other locations · NCT05784688

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.